secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001628280-22-012620
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q1 2022: cash $129.4M; mCRC trial shows improved ORR/PFS vs historical controls
--------------------------------------------------------------------------------

- Cash, equivalents & short-term investments ~$129.4M as of Mar 31, 2022; net cash used in ops $10.2M.
- R&D expense $7.2M (up $3.9M YoY); SG&A $3.9M (up $1.7M YoY) on higher CMC, headcount, stock comp.
- Phase 1b/2 mCRC: 34% initial ORR, 29% confirmed at RP2D (15 mg/m²) vs historical 5-13%; mPFS 9.4 months across all doses.
- Phase 2 mCRPC: 75% disease control at 12 weeks in highest dose-density arm; mutations in PTEN/MTOR linked to response.
- Preclinical: onvansertib+olaparib showed significant survival benefit vs each alone in PARPi-resistant ovarian PDX models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022012620/0001628280-22-012620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022012620/crdf-20220505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-012620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer